Establishes the "small cannabis farmer relief act" to allow certain cultivators to expand their canopy.
Summary
This bill establishes the “small cannabis farmer relief act” and creates a temporary limited canopy expansion program for certain New York cannabis cultivators. Specifically, a licensee that qualifies as a distressed farmer and legally cultivated cannabis in calendar year 2022 or 2023 may apply to expand its cultivation canopy to up to twice the square footage it cultivated in one of those years, so long as the expansion does not exceed the maximum size allowed for its cultivation tier. The bill also extends eligibility to microbusiness licensees that previously held an adult-use conditional cultivator license.
The measure sets out an application and review process through the cannabis office, allows denials to be appealed to the Cannabis Control Board, and prohibits the assessment of additional fees for the authorized canopy expansion, including standard renewal fees. It also preserves existing limits by making clear that no licensee may expand beyond the maximum canopy size otherwise permitted under the Cannabis Law and related regulations, and that all expansions remain subject to environmental, security, and testing requirements. The act takes effect immediately and expires on December 31, 2028.
Impact
The bill amends the New York Cannabis Law by adding a new section authorizing a targeted, temporary canopy expansion for qualifying distressed farmers and certain microbusiness cultivators. It affects cannabis cultivators and the state cannabis regulatory agencies by creating a new administrative approval process, an appeal path to the Cannabis Control Board, and a fee waiver for covered expansions. The bill does not broadly change cultivation rules for all licensees; instead, it creates a limited exception within existing tier and regulatory caps.
Sentiment
The available context suggests the bill is intended as relief legislation for small and distressed cannabis farmers, with a generally supportive policy goal of helping early cultivators scale up and remain viable. Because there are no committee transcripts or recorded votes provided, there is no direct evidence of opposition or formal debate in the supplied materials. The bill’s structure, including its temporary duration and continued regulatory limits, suggests an effort to balance industry relief with oversight and compliance concerns.
Contention
The main potential points of contention are likely to be who qualifies as a “distressed farmer,” how prior cultivation in 2022 or 2023 is verified, and whether expanding canopy capacity could create competitive or market-balance concerns. Another possible issue is regulatory control, since the bill gives the cannabis office authority to review applications and the Cannabis Control Board authority to hear appeals, which may raise questions about administrative burden and consistency. Supporters would likely emphasize relief for small operators and fee waivers, while any skeptics may focus on whether the expansion could exceed intended market limits or complicate enforcement.
Enacts the "small cannabis farmer relief act" in relation to authorizing certain licensees who qualify as distressed farmer licensees and who legally cultivated cannabis during the two thousand twenty-two or two thousand twenty-three calendar year to expand their cultivation canopy.
Medical cannabis combination business plant canopy increase to cultivate cannabis sold as medical cannabis flower or medical cannabinoid products provision
Plant canopy that a medical cannabis combination business may use to cultivate cannabis that will be sold as medical cannabis flower or medical cannabinoid products increased.
Requires Cannabis Regulatory Commission to monitor prices and to establish price cap on prices, under certain conditions, regarding medical cannabis cultivators, manufacturers, dispensaries, and clinical registrants.
Requires Cannabis Regulatory Commission to monitor prices and to establish price cap on prices, under certain conditions, regarding medical cannabis cultivators, manufacturers, dispensaries, and clinical registrants.
Manufacture of certain products for sale outside of Minnesota provided, tetrahydrocannabivarin designated as a nonintoxicating cannabinoid, potency limits modified, social equity ownership requirements lowered to 51 percent, manufacturing limits established, and cannabis cultivator license authorizations clarified.